Severe microangiopathic hemolytic anemia and thrombocytopenia in a child with Brucella infection

2001 ◽  
Vol 80 (9) ◽  
pp. 546-548 ◽  
Author(s):  
A. Yaramis ◽  
M. Kervancioglu ◽  
I. Yildirim ◽  
M. Soker ◽  
O. Derman ◽  
...  
Keyword(s):  
Hemolytic Anemia ◽  
Microangiopathic Hemolytic Anemia ◽  
Brucella Infection

Microangiopathic hemolytic anemia and severe thrombocytopenia in Brucella infection

1995 ◽  
Vol 70 (1) ◽  
pp. 59-60 ◽  
Author(s):  
A. Di Mario ◽  
S. Sica ◽  
G. Zini ◽  
P. Salutari ◽  
G. Leone
Keyword(s):  
Hemolytic Anemia ◽  
Severe Thrombocytopenia ◽  
Microangiopathic Hemolytic Anemia ◽  
Brucella Infection

Cancer-Related Microangiopathic Hemolytic Anemia

Medicine ◽  
2012 ◽  
Vol 91 (4) ◽  
pp. 195-205 ◽  
Author(s):  
Klaus Lechner ◽  
Hanna Lena Obermeier
Keyword(s):  
Hemolytic Anemia ◽  
Microangiopathic Hemolytic Anemia

scholarly journals Sunitinib-Induced Microangiopathic Hemolytic Anemia: A Case Report

2014 ◽  
Vol 36 (2) ◽  
pp. 88-90 ◽  
Author(s):  
Serdal Korkmaz ◽  
Saadettin Kilickap ◽  
Hatice Terzi ◽  
Mehmet Sencan
Keyword(s):  
Case Report ◽  
Hemolytic Anemia ◽  
Microangiopathic Hemolytic Anemia

scholarly journals How I Treat Microangiopathic Hemolytic Anemia in Patients with Cancer

Blood ◽  
2021 ◽  
Author(s):  
Mari Thomas ◽  
Marie Scully
Keyword(s):  
Hemolytic Anemia ◽  
Thrombus Formation ◽  
Bone Marrow Involvement ◽  
Diagnosis And Treatment ◽  
Microangiopathic Hemolytic Anemia ◽  
Drug Induced ◽  
Oncology Patient ◽  
Patients With Cancer ◽  
Underlying Malignancy ◽  
Atypical Haemolytic Uraemic Syndrome

Microangiopathic hemolytic anemia (MAHA) in patients with cancer requires urgent diagnosis and treatment. MAHA associated with thrombocytopenia, suggests a thrombotic microangiopathy (TMA), where there is thrombus formation affecting small or larger vessels. It may be directly related to the underlying malignancy (either the initial presentation or with progressive disease); to its treatment or it may be a separate incidental diagnosis. Although less common, it is vital to differentiate incidental thrombotic thrombocytopenia purpura (TTP) or atypical haemolytic uraemic syndrome (aHUS) in cancer patients presenting with a TMA as quickly as possible, as they have different treatment strategies, and prompt initiation of treatment has a critical impact on outcome. In the oncology patient, widespread microvascular metastases or extensive bone marrow involvement can cause MAHA and thrombocytopenia. A disseminated intravascular coagulation (DIC) picture may be precipitated by sepsis or driven by the cancer itself. Cancer therapies may cause a TMA either by dose-dependent toxicity, or an idiosyncratic immune-mediated reaction after development of drug-dependent antibodies. Many of the causes of TMA seen in the oncology patient do not respond to plasma exchange and, where feasible, treatment of the underlying malignancy is important in controlling both cancer-TMA and DIC driven by the disease. The potential for drug-induced TMA should be considered and any putative causal agent stopped. We will discuss the differential diagnosis and treatment of MAHA in patients with cancer using clinical cases to highlight management principles.

Sign in / Sign up

Export Citation Format

Share Document